Logo

Novo Nordisk Signs Non -Exclusive Agreement with Abbott for its FreeStyle Libre Mobile App

Share this

Novo Nordisk Signs Non -Exclusive Agreement with Abbott for its FreeStyle Libre Mobile App

Shots:

  • The companies entered into an agreement to assess insulin dose data from Novo Nordisk’ pre-filled insulin pen connected to the digital health tool marked with Abbott’s FreeStyle Libre system (FreeStyle LibreLink mobile app and LibreView cloud-based system)
  • The focus of an agreement is to advance management techniques for diabetes with the combination of the two technologies CGM & connected insulin pen- enabling healthcare professionals to monitor glucose and insulin data
  • In H1’17- Novo signed a collaboration with Glooko for its platform connected to insulin pens for uploading data by any means of communication-capable Android phone. Abbott's FreeStyle Libre system uses sensors allowing the monitor glucose levels in real-time with an eight-hour glucose history & change in glucose level

Ref: Abbott | Image:  Abbott

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions